Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report

Omar El Mesbahi,Affaf Amarti,Siham Tizniti,Kaoutar Znati,Anas Touyar,Abdelmalek Ossaden,Yousra Akasbi,Adil Ibrahimi,Fatima Zahra El Mrabet,Sami Aziz Brahmi,Khalid Maazaz,Khalid Ait Taleb

doi:10.1186/1752-1947-5-197

Omar El Mesbahi, Affaf Amarti + Show 10 more

Open Access

https://doi.org/10.1186/1752-1947-5-197

Copy DOI

Abstract

IntroductionGastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors. Although the response rate in patients treated with imatinib mesylate in prospective clinical studies is above 50%, a complete response is very rare. We report the case of a patient with a gastric gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate.Case presentationWe report the case of a 54-year-old Arab woman with a gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate.ConclusionThe pathological examination of our patient documented a complete pathological response after imatinib therapy. Recently, it has been confirmed that the kinase genotype of KIT and platelet-derived growth factor receptor α can accurately predict a good response to imatinib mesylate therapy. We propose that this patient had a mutation conferring high sensitivity to imatinib mesylate.

Highlights

Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit
Case presentation: We report the case of a 54-year-old Arab woman with a gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate
It has been confirmed that the kinase genotype of KIT and platelet-derived growth factor receptor a can accurately predict a good response to imatinib mesylate therapy

Summary

Conclusion

The pathological examination of our patient documented a complete response after IM therapy. It has been confirmed that the kinase genotypes of KIT and PDGFRA a can accurately predict a good response to IM therapy. We propose that this patient had a mutation conferring high sensitivity to IM. Consent Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal

Introduction

Discussion